In recent years, there has been increasing interest in designing multi‐target agents that improve efficacy and safety compared to their single target counterparts.Cyclooxygenase‐2 (COX‐2) selective inhibitors (coxibs) are effective drugs for treating inflammation, pain, and cancer. However, their mechanism‐based side effects limit their use. Meanwhile, soluble epoxide hydrolase (sEH) is involved in the metabolism of fatty acid epoxides that are obtained by cytochrome P450 (CYP) from arachidonic acid. These CYP metabolites, epoxyeicosatrienoic acids (EETs), are anti‐hypertensive, anti‐inflammatory, analgesic and organ‐protective. Therefore, co‐inhibition of both enzymes with a combination treatment is synergistic and is maximized by combining both actions into a single molecule, such as PTUPB. These dual inhibitors showed superior efficacy in several rodent models of inflammatory pain, metabolic syndrome, and cancer.We found that they inhibit COX‐2 tightly and in a time‐dependent manner (25‐fold more potent) and EETs moderately inhibit COX‐2. Computational studies of their binding modes at the active site of enzymes using molecular docking confirm these results. In addition to these studies, water‐soluble prodrugs of these dual inhibitors were developed for their use in animal studies.Support or Funding InformationThis work was supported in part by NIEHS grant R01ES02710, NIEHS Superfund Basic Research Program grant P42 ES04699, National Institute of Neurological Disorders and Stroke (NINDS) U54 NS079202. NIH 5T32DC008072‐05.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Read full abstract